[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$five8vuBH2pDKRjpsJ3otsWBd25NhthzRt1Z0l9z63tw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":43,"rows":50},"Centre Hospitalier Régional d'Orléans",[4],124,false,27,2,29125,111,[13,16,19,21,24,26,28,30],{"name":14,"count":15},"Healthy",12,{"name":17,"count":18},"Parkinson Disease",4,{"name":20,"count":18},"Stroke",{"name":22,"count":23},"Stroke, Acute",3,{"name":25,"count":23},"Multiple Sclerosis",{"name":27,"count":23},"Intensive Care Unit",{"name":29,"count":23},"COVID-19",{"name":31,"count":23},"Critical Illness",[33,38],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06589258","Cannabidiol Into Breastmilk","2027-10","Assessing maternal and lactational plasma CBD uptake at different stages of breastfeeding",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04160455","Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.","2029-11-07","expression of a panel",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,79,101,134,160,178,202,227,254,281,299,324,348,374,400],{"intervention":42,"totalTrials":52,"cells":53},1,{"EARLY_PHASE1":54,"PHASE1":57,"PHASE2":59,"PHASE3":61,"PHASE4":63,"NA":65},{"trials":55,"activeCount":56},[],0,{"trials":58,"activeCount":56},[],{"trials":60,"activeCount":56},[],{"trials":62,"activeCount":56},[],{"trials":64,"activeCount":56},[],{"trials":66,"activeCount":52,"soonestReadout":41},[67],{"nctId":39,"briefTitle":40,"status":68,"phases":69,"primaryCompletion":41,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":78},"RECRUITING",[],"2039-11-07","2019-11-07",180,[74,75,76,77],"Autophagy","Galectins","HIV Infections","Highly Active Antiretroviral Therapy",[42],{"intervention":37,"totalTrials":52,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":89,"NA":91},{"trials":82,"activeCount":56},[],{"trials":84,"activeCount":56},[],{"trials":86,"activeCount":56},[],{"trials":88,"activeCount":56},[],{"trials":90,"activeCount":56},[],{"trials":92,"activeCount":52,"soonestReadout":36},[93],{"nctId":34,"briefTitle":35,"status":68,"phases":94,"primaryCompletion":36,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":100},[49],"2028-10","2025-10-06",60,[99],"Breast Feeding",[37],{"intervention":102,"totalTrials":52,"cells":103},"Biological samples",{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":132},{"trials":105,"activeCount":56},[],{"trials":107,"activeCount":56},[],{"trials":109,"activeCount":56},[],{"trials":111,"activeCount":56},[],{"trials":113,"activeCount":56},[114],{"nctId":115,"briefTitle":116,"status":117,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":131},"NCT04952766","Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults","COMPLETED",[48],"2022-02-06","2021-03-26",196,[123,124,125,126,25,127,128,129,130],"Kidney Transplant","Myeloma","Cancer","Hematologic Malignancy","Hypergammaglobulinemia","Malignant Tumor","Hiv","Diabetes Type 2",[102],{"trials":133,"activeCount":56},[],{"intervention":135,"totalTrials":52,"cells":136},"Norepinephrine",{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":158},{"trials":138,"activeCount":56},[],{"trials":140,"activeCount":56},[],{"trials":142,"activeCount":56},[],{"trials":144,"activeCount":56},[],{"trials":146,"activeCount":56},[147],{"nctId":148,"briefTitle":149,"status":117,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":6,"conditions":153,"interventions":156},"NCT03849508","Phenylephrine Versus Norepinephrine for Maintenance of Hemodynamic During Cesarean Section Under Spinal Anesthesia",[48],"2020-12-02","2019-02-27",[154,155],"Cesarean Section Complications","Spinal Anesthesia",[135,157],"Phenylephrine",{"trials":159,"activeCount":56},[],{"intervention":157,"totalTrials":52,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":176},{"trials":163,"activeCount":56},[],{"trials":165,"activeCount":56},[],{"trials":167,"activeCount":56},[],{"trials":169,"activeCount":56},[],{"trials":171,"activeCount":56},[172],{"nctId":148,"briefTitle":149,"status":117,"phases":173,"primaryCompletion":151,"completion":151,"start":152,"enrollment":6,"conditions":174,"interventions":175},[48],[154,155],[135,157],{"trials":177,"activeCount":56},[],{"intervention":179,"totalTrials":52,"cells":180},"subcutaneous tocilizumab",{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":200},{"trials":182,"activeCount":56},[],{"trials":184,"activeCount":56},[],{"trials":186,"activeCount":56},[],{"trials":188,"activeCount":56},[],{"trials":190,"activeCount":56},[191],{"nctId":192,"briefTitle":193,"status":117,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":97,"conditions":197,"interventions":199},"NCT02765074","Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis",[48],"2025-04-03","2016-06-30",[198],"Rheumatoid Arthritis",[179],{"trials":201,"activeCount":56},[],{"intervention":203,"totalTrials":52,"cells":204},"Hydrocortisone administration",{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":211,"PHASE4":213,"NA":225},{"trials":206,"activeCount":56},[],{"trials":208,"activeCount":56},[],{"trials":210,"activeCount":56},[],{"trials":212,"activeCount":56},[],{"trials":214,"activeCount":56},[215],{"nctId":216,"briefTitle":217,"status":117,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":224},"NCT04137302","Administration of Hydrocortisone in Young Healthy Male Volunteers",[48],"2020-01-31","2019-11-13",21,[223],"Anti-doping Campaign, Detection of Hydrocortisone",[203],{"trials":226,"activeCount":56},[],{"intervention":228,"totalTrials":52,"cells":229},"hydrocortison hemisuccinate",{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":250,"NA":252},{"trials":231,"activeCount":56},[],{"trials":233,"activeCount":56},[],{"trials":235,"activeCount":56},[],{"trials":237,"activeCount":56},[238],{"nctId":239,"briefTitle":240,"status":241,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":249},"NCT01817153","Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.","TERMINATED",[46,47],"2019-11-05","2013-11-05",10,[247,248],"Septic Shock","Adult",[228],{"trials":251,"activeCount":56},[],{"trials":253,"activeCount":56},[],{"intervention":255,"totalTrials":52,"cells":256},"dolutegravir 50mg +abacavir 600mg +lamivudine 300mg",{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":277,"NA":279},{"trials":258,"activeCount":56},[],{"trials":260,"activeCount":56},[],{"trials":262,"activeCount":56},[],{"trials":264,"activeCount":56},[265],{"nctId":266,"briefTitle":267,"status":241,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":275},"NCT02596334","Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients",[47],"2017-06-23","2018-06-23","2015-12-23",158,[274],"HIV",[255,276],"dolutegravir",{"trials":278,"activeCount":56},[],{"trials":280,"activeCount":56},[],{"intervention":276,"totalTrials":52,"cells":282},{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":295,"NA":297},{"trials":284,"activeCount":56},[],{"trials":286,"activeCount":56},[],{"trials":288,"activeCount":56},[],{"trials":290,"activeCount":56},[291],{"nctId":266,"briefTitle":267,"status":241,"phases":292,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":293,"interventions":294},[47],[274],[255,276],{"trials":296,"activeCount":56},[],{"trials":298,"activeCount":56},[],{"intervention":300,"totalTrials":52,"cells":301},"CBD LGP 50",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":318,"PHASE4":320,"NA":322},{"trials":303,"activeCount":56},[],{"trials":305,"activeCount":56},[],{"trials":307,"activeCount":56},[308],{"nctId":309,"briefTitle":310,"status":117,"phases":311,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT05306249","Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients",[46],"2023-02-08","2022-05-16",80,[316],"HIV Seropositivity",[300],{"trials":319,"activeCount":56},[],{"trials":321,"activeCount":56},[],{"trials":323,"activeCount":56},[],{"intervention":325,"totalTrials":52,"cells":326},"Blood sample",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":337},{"trials":328,"activeCount":56},[],{"trials":330,"activeCount":56},[],{"trials":332,"activeCount":56},[],{"trials":334,"activeCount":56},[],{"trials":336,"activeCount":56},[],{"trials":338,"activeCount":56},[339],{"nctId":340,"briefTitle":341,"status":117,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT05746845","Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis",[],"2024-07-01","2023-03-06",100,[14,25],[325],{"intervention":349,"totalTrials":52,"cells":350},"fluid bolus",{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":352,"activeCount":56},[],{"trials":354,"activeCount":56},[],{"trials":356,"activeCount":56},[],{"trials":358,"activeCount":56},[],{"trials":360,"activeCount":56},[],{"trials":362,"activeCount":56},[363],{"nctId":364,"briefTitle":365,"status":241,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":373},"NCT02645851","RApid Fluid Volume EXpansion in Patients in Shock After the Initial Phase of Resuscitation.",[49],"2024-05-04","2016-01-16",98,[371,372],"Shock","Hypovolemia",[349],{"intervention":375,"totalTrials":52,"cells":376},"Blood sample and Cerebrospinal fluid (CSF) collection.",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":387},{"trials":378,"activeCount":56},[],{"trials":380,"activeCount":56},[],{"trials":382,"activeCount":56},[],{"trials":384,"activeCount":56},[],{"trials":386,"activeCount":56},[],{"trials":388,"activeCount":56},[389],{"nctId":390,"briefTitle":391,"status":392,"phases":393,"primaryCompletion":394,"completion":394,"start":394,"enrollment":56,"conditions":395,"interventions":399},"NCT04674163","Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases.","WITHDRAWN",[49],"2023-01",[396,397,398],"Sclerosis, Multiple","Guillain-Barre Syndrome","Inflammation",[375],{"intervention":401,"totalTrials":52,"cells":402},"Blood and fecal samples",{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":404,"activeCount":56},[],{"trials":406,"activeCount":56},[],{"trials":408,"activeCount":56},[],{"trials":410,"activeCount":56},[],{"trials":412,"activeCount":56},[],{"trials":414,"activeCount":56},[415],{"nctId":416,"briefTitle":417,"status":117,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":426},"NCT05916274","Exploration of the Activity of DNA Located Outside of Cellular Nucleus to Amplify Inflammation in Inflammatory Bowel Disease in Children Through Biological Pathway Cyclic GMP-AMP Synthase (cGAS) - Stimulator of Interferon Genes (STING)",[49],"2024-02-29","2023-05-31",40,[423,424,425],"Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis",[401]]